Selective bladder preservation with curative intent for muscle‐invasive bladder cancer: A contemporary review
Authors:
- 12 March 2012
- journal article
- review article
- Published by Wiley in International Journal of Urology
- Vol. 19 (5) , 388-401
Abstract
Radical cystectomy plus urinary diversion, the reference standard treatment for muscle-invasive bladder cancer, associates with high complication rates and compromises quality of life as a result of long-term effects on urinary, gastrointestinal and sexual function, and changes in body image. As a society ages, the number of elderly patients unfit for radical cystectomy as a result of comorbidity will increase, and thus the demand for bladder-sparing approaches for muscle-invasive bladder cancer will also inevitably increase. Trimodality bladder-sparing approaches consisting of transurethral resection, chemotherapy and radiotherapy (Σ 55-65 Gy) yield overall survival rates comparable with those of radical cystectomy series (50-70% at 5 years), while preserving the native bladder in 40-60% of muscle-invasive bladder cancer patients, contributing to an improvement in quality of life for such patients. Limitations of the trimodality therapy include (i) muscle-invasive bladder cancer recurrence in the preserved bladder, which most often arises in the original muscle-invasive bladder cancer site; (ii) potential lack of curative intervention for regional lymph nodes; and (iii) increased morbidity in the event of salvage radical cystectomy for remaining or recurrent disease as a result of high-dose pelvic irradiation. Consolidative partial cystectomy with pelvic lymph node dissection followed by induction chemoradiotherapy at lower dose (e.g. 40 Gy) is a rational strategy for overcoming such limitations by strengthening locoregional control and reducing radiation dosage. Molecular profiling of the tumor and functional imaging might play important roles in optimal patient selection for bladder preservation. Refinement of radiation techniques, intensified concurrent or adjuvant chemotherapy, and novel sensitizers, including molecular targeting agent, are also expected to improve outcomes and consequently provide more muscle-invasive bladder cancer patients with favorable quality of life.Keywords
This publication has 96 references indexed in Scilit:
- Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcomeBJU International, 2009
- Bladder preservation: optimizing radiotherapy and integrated treatment strategiesBJU International, 2008
- Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertaintiesNature Clinical Practice Oncology, 2008
- Measuring health‐related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI)Cancer, 2007
- Trimodality Treatment and Selective Organ Preservation for Bladder CancerJournal of Clinical Oncology, 2006
- Complications after radical cystectomy: Analysis of population-based dataUrology, 2006
- Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectivesInternational Journal of Clinical Oncology, 2004
- Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term ResultsJournal of Clinical Oncology, 2002
- Bladder preservation by combined modality therapy for invasive bladder cancer.Journal of Clinical Oncology, 1997
- Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study.Journal of Clinical Oncology, 1993